BCAC media release, 5 December 2019
Breast Cancer Aotearoa Coalition (BCAC) is delighted to learn that fulvestrant (Faslodex) will be funded by PHARMAC in the New Year, BCAC Chair Libby Burgess says.
We are very grateful to LeRêve (NZ), a direct selling company, for taking part in an Australasian fun run to raise money for BCAC. Forty-five LeRêve (NZ) consultants, staff, friends and family travelled to the Gold Coast to run or walk 5km in the event with their Australian counterparts.
Wellingtonian Lachlan McKenzie is excited he completed his first ever marathon in good time on Saturday 16 November in Queenstown, raising money for BCAC.
Media release, 1 October 2019
BCAC is extremely disappointed to read that access to cancer medicines does not appear to be a priority for New Zealand’s new cancer control agency according to its national director, Diana Sarfati, in a recent interview.
Lachlan McKenzie is running the Queenstown Marathon in November to raise money for BCAC and says he is loving the training.
When Ethna Renner was diagnosed with breast cancer in 2019, it was the most daunting news she had ever received. Suddenly she was faced with something she had no control over.
Metavivors and BCAC are delighted that two vital breast cancer medicines will soon be funded.
Breast Cancer Aotearoa Coalition (BCAC) stands with all people living with advanced breast cancer and their supporters who have advocated for changes in medicines funding and the health system.
Today (8 August 2019) PHARMAC released a proposal to fund Kadcyla (trastuzumab emtansine, T-DM1) for women with advanced HER2 positive breast cancer.